【摘要】 [目的]观察FOLFOX4方案治疗晚期大肠癌的疗效及毒副反应。[方法]对52例初治或复治的晚期大肠癌患者,予FOLFOX4方案化疗(奥沙利铂+亚叶酸钙+5-氟尿嘧啶)。[结果]全组52例均可评价疗效及毒副反应。总有效率为30.7%。初治患者CR1例,PR8例,SD10例,PD2例,有效率为45%;中位疾病进展时间10个月,中位生存期17个月。复治患者PR7例,SD20例,PD5例,有效率为21.9%;中位疾病进展时间6个月,平均生存期12个月。毒副反应主要为中性粒细胞减少、消化道反应和神经毒性,以Ⅰ～Ⅱ度为主。[结论]FOLFOX4方案治疗晚期大肠癌疗效肯定,安全性好。更多还原

【Abstract】 [Purpose] To evaluate the efficacy and toxicity of FOLFOX4 regimen in the treatment for advanced colorectal cancer. [Methods] Fifty-two initially treated or re-treated patients with advanced colorectal cancer were treated with FOLFOX4 regimen (Oxaliplatin+CF+5-Fu). [Results] All 52 cases were eligible for efficacy and toxicity evaluation. The overall response rate was 30.7%. Of the initially treated cases, the response rate was 45%, including complete response(CR) in 1 case; partial response (PR) in 7 cases; stable disease (SD) in 13 cases; and progress disease (PD) in 1 case. The median time to tumor progression (TTP) was 10 months, and the median overall survival (OS) was 17 months. Of the re-treated cases, the response rate was 21.9%, including PR in 7 cases; SD in 20 cases and PD in 5 cases. The median TTP was 6 months, and the median OS was 12 months. The main toxicity was neutropenia, gastrointestinal toxicity and neurotoxicity with grade Ⅰ or Ⅱ. [Conclusion] FOLFOX4 regimen is effective and safety for patients with advanced colorectal cancer.更多还原